Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Antimicrob Agents Chemother
2012 May 01;565:2283-9. doi: 10.1128/AAC.00166-12.
Show Gene links
Show Anatomy links
Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.
Martin RE
,
Butterworth AS
,
Gardiner DL
,
Kirk K
,
McCarthy JS
,
Skinner-Adams TS
.
???displayArticle.abstract???
The antiretroviral protease inhibitors (APIs) ritonavir, saquinavir, and lopinavir, used to treat HIV infection, inhibit the growth of Plasmodium falciparum at clinically relevant concentrations. Moreover, it has been reported that these APIs potentiate the activity of chloroquine (CQ) against this parasite in vitro. The mechanism underlying this effect is not understood, but the degree of chemosensitization varies between the different APIs and, with the exception of ritonavir, appears to be dependent on the parasite exhibiting a CQ-resistant phenotype. Here we report a study of the role of the P. falciparum chloroquine resistance transporter (PfCRT) in the interaction between CQ and APIs, using transgenic parasites expressing different PfCRT alleles and using the Xenopus laevis oocyte system for the heterologous expression of PfCRT. Our data demonstrate that saquinavir behaves as a CQ resistance reverser and that this explains, at least in part, its ability to enhance the effects of CQ in CQ-resistant P. falciparum parasites.
Allen,
Plasmodium falciparum culture: the benefits of shaking.
2010, Pubmed
Allen,
Plasmodium falciparum culture: the benefits of shaking.
2010,
Pubmed
Andrews,
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.
2006,
Pubmed
Berenbaum,
A method for testing for synergy with any number of agents.
1978,
Pubmed
Canfield,
Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.
1995,
Pubmed
Djimdé,
A molecular marker for chloroquine-resistant falciparum malaria.
2001,
Pubmed
Dubar,
The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance.
2011,
Pubmed
Ferreira,
Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in Plasmodium falciparum.
2006,
Pubmed
Fidock,
Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance.
2000,
Pubmed
Foote,
Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum.
1990,
Pubmed
Ford,
The intracellular pharmacology of antiretroviral protease inhibitors.
2004,
Pubmed
Hasegawa,
pKa determination of verapamil by liquid-liquid partition.
1984,
Pubmed
Hayward,
The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance.
2006,
Pubmed
He,
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
2008,
Pubmed
He,
Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.
2009,
Pubmed
Hocart,
4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses.
2011,
Pubmed
Kashuba,
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.
1999,
Pubmed
Kumar,
Synthesis of new 4-aminoquinolines and quinoline-acridine hybrids as antimalarial agents.
2010,
Pubmed
Launay,
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
2004,
Pubmed
Lehane,
Differential drug efflux or accumulation does not explain variation in the chloroquine response of Plasmodium falciparum strains expressing the same isoform of mutant PfCRT.
2011,
Pubmed
Martin,
Chloroquine transport via the malaria parasite's chloroquine resistance transporter.
2009,
Pubmed
,
Xenbase
Nsanzabana,
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
2011,
Pubmed
Olliaro,
The global portfolio of new antimalarial medicines under development.
2009,
Pubmed
Parikh,
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
2005,
Pubmed
Ray,
Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.
2010,
Pubmed
Redmond,
Antimalarial activity of sera from subjects taking HIV protease inhibitors.
2007,
Pubmed
Reed,
Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum.
2000,
Pubmed
Saliba,
pH regulation in the intracellular malaria parasite, Plasmodium falciparum. H(+) extrusion via a V-type H(+)-ATPase.
1999,
Pubmed
Sidhu,
Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations.
2002,
Pubmed
Sidhu,
pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum.
2005,
Pubmed
Skinner-Adams,
Synergistic in vitro antimalarial activity of omeprazole and quinine.
1999,
Pubmed
Skinner-Adams,
Antiretrovirals as antimalarial agents.
2004,
Pubmed
Skinner-Adams,
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
2007,
Pubmed
Su,
A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum.
1999,
Pubmed
Trager,
Human malaria parasites in continuous culture.
1976,
Pubmed
Ursing,
Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial.
2011,
Pubmed
Wellems,
Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross.
1990,
Pubmed
Wlodawer,
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
1998,
Pubmed
Yuan,
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
2011,
Pubmed
